Cystic Fibrosis
Also known as: CF
Methodology & AI Transparency ⓘ
Cystic Fibrosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cystic fibrosis (CF) is an inherited disease of the mucus and sweat glands.
- 2 Real-world patient consensus: Diagnostic registry E84.9: Cystic Fibrosis is managed within Lungs & Asthma (aka CF).
- 3 Typical cash cost range: Clinicians assessing Cystic Fibrosis focus on small-airway remodeling [Cystic Fibrosis E84.9] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Cystic Fibrosis: maintaining Fractional Exhaled Nitric in Cystic Fibrosis (E84.9: Oxide (FeNO)) within < 25 ppb (E84.9).
Ask our AI Specialists anything about Cystic Fibrosis
What Is Cystic Fibrosis?
Cystic fibrosis (CF) is an inherited disease of the mucus and sweat glands. It affects mostly your lungs, pancreas, liver, intestines, sinuses, and sex organs. CF causes your mucus to be thick and sticky. The mucus clogs the lungs, causing breathing problems and making it easy for bacteria to grow. This can lead to repeated lung infections and lung damage. The symptoms and severity of CF can vary. Some people have serious problems from birth. Others have a milder version of the disease that doesn't show up until they are teens or young adults. Sometimes you will have few symptoms, but later you may have more symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Cystic Fibrosis (E84.9) features small-airway remodeling [Cystic Fibrosis E84.9]. Cross-referenced with NIH MeSH (Cystic Fibrosis), therapeutic stabilization in lungs & asthma is verified against Resting Pulse Oximetry in Cystic Fibrosis (E84.9: (SpO2)).
Common Symptoms & Clinical Signs
- • Presentation of Cystic Fibrosis (E84.9): chronic productive or in Cystic Fibrosis (E84.9: dry cough worsening)
- • Secondary Cystic Fibrosis clinical sign: prolonged recovery from in Cystic Fibrosis (E84.9: viral respiratory infections)
- • Symptom flares in Cystic Fibrosis correlating with Fractional Exhaled Nitric in Cystic Fibrosis (E84.9: Oxide (FeNO)) deviation outside < 25 ppb (E84.9)
- • Functional lungs & asthma impact requiring post-bronchodilator spirometry [Cystic Fibrosis E84.9] evaluation (E84.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cystic Fibrosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E84.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fractional Exhaled Nitric in Cystic Fibrosis (E84.9: Oxide (FeNO)) | < 25 ppb (E84.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Cystic Fibrosis (E84.9: (SpO2)) | 96% – 100% (E84.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Cystic Fibrosis E84.9] | < 150 cells/uL (phenotyping marker) (E84.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cystic Fibrosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Vanzacaftor, Tezacaftor, and Deutivacaftor Alyftrek • RxCUI RXN-51167121-3011 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | 83% | $1.7800 | $ 80.59 /mo |
| Tezacaftor and Ivacaftor Symdeko • RxCUI 1243046 | FDA Prescription Therapeutic Agent | 81% | $3.0000 | $ 130.00 /mo |
| Ivacaftor Kalydeco • RxCUI RXN-51167300-2525 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | 92% | $0.4400 | $ 26.32 /mo |
| Tobramycin Solution Tobramycin Solution Generic • RxCUI 348719 | Aminoglycoside Antibacterial | 91% | $1.0548 | $ 51.22 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cystic Fibrosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of N -Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and: What a 2,515-Participant Study Found NAC had a major effect on progesterone, endometrial thickness, and LH levels in women with PCOS. Nutrients • 2025-01-14 • Meta-Analysis | N = 2,515 | 99/100 | PMID 39861414 ↗ |
| New Insights on Effectiveness of myoinositol for polycystic ovary: What a 573-Participant Study Found Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS. Endocrine • 2018-01-15 • Meta-Analysis | N = 573 | 97/100 | PMID 29052180 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
| New Insights on Reproductive hormone characteristics of obese Chinese patients with polycystic: What a 4,554-Participant Study Found Conversely, they exhibited significantly higher testosterone (T) ( p = 0.001) levels. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2025-12-15 • Meta-Analysis | N = 4,554 | 94/100 | PMID 40287875 ↗ |
| New Insights on Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy: What a 742-Participant Study Found HDM SLIT-tablet AIT is efficacious in HDM-sensitised asthma subjects with a genetic asthma predisposition and/or an underlying T2 endotype. Thorax • 2024-03-15 • Phase III Randomized Trial | N = 742 | 93/100 | PMID 38160049 ↗ |
Cystic Fibrosis Patient Community & “People Like Me” Threads
Filter Cystic Fibrosis community threads and patient logs by age, biological sex, dosage, and treatment duration.